Song Xiaochun, Zhang Cui, Chen Xin, Chen Yongming, Shi Qiankun, Niu Yongsheng, Xiao Jilai, Mu Xinwei
Department of Intensive Care Unit (ICU), Nanjing Hospital Affiliated to Nanjing Medical University, Qinhuai district, No. 68 Changle Road, Nanjing, 210006, Jiangshu, China.
Department of Thoracic and Cardiovascular Surgery, Nanjing Hospital Affiliated to Nanjing Medical University, Qinhuai district, No. 68 Changle Road, Nanjing, 210006, Jiangshu, China.
J Cardiothorac Surg. 2015 May 13;10:70. doi: 10.1186/s13019-015-0274-1.
Observe the efficacy of surgical treatment in patients with severe pulmonary arterial hypertension caused by mitral valve disease.
We examined the results of surgical treatment in 32 patients with mitral valve disease and severe pulmonary arterial hypertension (pulmonary arterial systolic pressure ≥ 80 mmHg) retrospectively. Operative and postoperative data collection included type of the surgery, cardiopulmonary bypass time, cross-clamp time and the mortality rate. Pulmonary arterial systolic pressure, left atrial diameter, left ventricular end-diastolic diameter, and left ventricular ejection fraction were recorded and compared.
A total number of 32 patients had the operation of mitral valve replacement. Among those subjects, twenty-seven patients were surgically replaced with mechanical prosthesis and five patients with tissue prosthesis. Only one patient died of pneumonia, with a mortality rate of 3.1 %. The statistical results of preoperative and postoperative echocardiographic data showed significant decrease in pulmonary arterial systolic pressure (101.2 ± 20.3 versus 48.1 ± 14.3 mmHg, P < 0.05), left atrial diameter(67.6 ± 15.7 versus 54.4 ± 11.4 mm, P < 0.05) and left ventricular end-diastolic diameter (52.3 ± 9.5 versus 49.2 ± 5.9 mm, P < 0.05). There was no significant change in left ventricular ejection fraction (59.2 ± 6.5 versus 57.9 ± 7.6, P = NS). At the time of follow-up, twenty-eight (96.6 %) patients were classified in New York Heart Association functional class I or II, one(3.4 %) in class III, with the mortality rate is zero percent.
Mitral valve replacement can be performed successfully in patients with mitral valve disease and severe pulmonary arterial hypertension with an acceptable perioperative risk.
观察手术治疗二尖瓣疾病所致重度肺动脉高压患者的疗效。
回顾性分析32例二尖瓣疾病合并重度肺动脉高压(肺动脉收缩压≥80 mmHg)患者的手术治疗结果。手术及术后数据收集包括手术类型、体外循环时间、主动脉阻断时间和死亡率。记录并比较肺动脉收缩压、左心房内径、左心室舒张末期内径和左心室射血分数。
共有32例患者接受了二尖瓣置换手术。其中,27例患者接受了机械瓣膜置换,5例患者接受了生物瓣膜置换。仅1例患者死于肺炎,死亡率为3.1%。术前和术后超声心动图数据的统计结果显示,肺动脉收缩压(101.2±20.3对48.1±14.3 mmHg,P<0.05)、左心房内径(67.6±15.7对54.4±11.4 mm,P<0.05)和左心室舒张末期内径(52.3±9.5对49.2±5.9 mm,P<0.05)显著降低。左心室射血分数无显著变化(59.2±6.5对57.9±7.6,P=NS)。随访时,28例(96.6%)患者纽约心脏协会心功能分级为Ⅰ或Ⅱ级,1例(3.4%)为Ⅲ级,死亡率为零。
二尖瓣疾病合并重度肺动脉高压患者可成功进行二尖瓣置换手术,围手术期风险可接受。